The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome
Purpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/1246129 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563633224155136 |
|---|---|
| author | Eva Novosadova Alzbeta Chabronova Vitezslav Kolek Martin Petrek Zdenka Navratilova |
| author_facet | Eva Novosadova Alzbeta Chabronova Vitezslav Kolek Martin Petrek Zdenka Navratilova |
| author_sort | Eva Novosadova |
| collection | DOAJ |
| description | Purpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to the presence of Löfgren’s syndrome (LS) as a hallmark of good prognosis in contrast to more advanced disease course. Methods. RT-PCR was used to assess 35 miRNAs in 13 healthy controls and 24 sarcoidosis patients (12 with X-ray (CXR) stage ≤ 1 and LS and 12 with insidious onset and CXR stage ≥ 3). Results. Compared to controls, we consistently observed dysregulated expressions of miR-146, miR-16, miR-425-5p, and miR-93-5p in both sarcoidosis groups irrespective of disease course. Specifically, patients without LS had dysregulated expressions of miR-150-5p, miR-1, and miR-212 compared to controls. Patients with LS had dysregulated expressions of miR-21-5p and miR-340-5p compared to controls. Bioinformatics predicted consistently “Pathways in cancer” to be modulated by both altered profiles in patients with/without LS. Three miRNAs (miR-21-5p, miR-340-5p, and miR-212-3p) differed between our patients with LS and those without LS; their cumulative effect may modulate “TGF-β signalling pathway.” Conclusions. Further study should focus on possible applications of serum miRNAs for diagnostics follow-up and for prognosis. |
| format | Article |
| id | doaj-art-505ea493748846c480da77325ce6844f |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-505ea493748846c480da77325ce6844f2025-02-03T01:13:03ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/12461291246129The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s SyndromeEva Novosadova0Alzbeta Chabronova1Vitezslav Kolek2Martin Petrek3Zdenka Navratilova4Laboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech RepublicLaboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech RepublicDepartment of Respiratory Medicine and TBC, Palacky University, Olomouc, Czech RepublicLaboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech RepublicLaboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech RepublicPurpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to the presence of Löfgren’s syndrome (LS) as a hallmark of good prognosis in contrast to more advanced disease course. Methods. RT-PCR was used to assess 35 miRNAs in 13 healthy controls and 24 sarcoidosis patients (12 with X-ray (CXR) stage ≤ 1 and LS and 12 with insidious onset and CXR stage ≥ 3). Results. Compared to controls, we consistently observed dysregulated expressions of miR-146, miR-16, miR-425-5p, and miR-93-5p in both sarcoidosis groups irrespective of disease course. Specifically, patients without LS had dysregulated expressions of miR-150-5p, miR-1, and miR-212 compared to controls. Patients with LS had dysregulated expressions of miR-21-5p and miR-340-5p compared to controls. Bioinformatics predicted consistently “Pathways in cancer” to be modulated by both altered profiles in patients with/without LS. Three miRNAs (miR-21-5p, miR-340-5p, and miR-212-3p) differed between our patients with LS and those without LS; their cumulative effect may modulate “TGF-β signalling pathway.” Conclusions. Further study should focus on possible applications of serum miRNAs for diagnostics follow-up and for prognosis.http://dx.doi.org/10.1155/2016/1246129 |
| spellingShingle | Eva Novosadova Alzbeta Chabronova Vitezslav Kolek Martin Petrek Zdenka Navratilova The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome Mediators of Inflammation |
| title | The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome |
| title_full | The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome |
| title_fullStr | The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome |
| title_full_unstemmed | The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome |
| title_short | The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome |
| title_sort | serum expression of selected mirnas in pulmonary sarcoidosis with without lofgren s syndrome |
| url | http://dx.doi.org/10.1155/2016/1246129 |
| work_keys_str_mv | AT evanovosadova theserumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT alzbetachabronova theserumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT vitezslavkolek theserumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT martinpetrek theserumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT zdenkanavratilova theserumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT evanovosadova serumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT alzbetachabronova serumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT vitezslavkolek serumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT martinpetrek serumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome AT zdenkanavratilova serumexpressionofselectedmirnasinpulmonarysarcoidosiswithwithoutlofgrenssyndrome |